Evidence map›Paper›PMID 39401890›Full record

ArticleTobacco control2024

Global landscape of nicotine and tobacco products additives policies.

Andre Luiz Oliveira da Silva, Stella Bialous

Abstract read
In one paragraph

Article in Tobacco control, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andre Luiz Oliveira da SilvaDIRE3/GGTAB/CCTAB, Brazilian Health Regulatory Agency (Anvisa), Rio de Janeiro, RJ, Brazil andre.sp.ensp@gmail.com.ORCID http://orcid.org/0000-0003-4768-959X
Stella BialousSchool of Nursing and Center for Tobacco Control Research and education, UCSF, San Francisco, California, USA.ORCID http://orcid.org/0000-0002-6471-5457

Funding

Addressing disparities in tobacco-related diseases by understanding the tobacco industry strategiesR01CA268491 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STELLA AGUINAGA BIALOUS, Pamela May Ling · 2022 to 2026
$3.4M
NCI NIH HHS R01 CA268491
6 · The paper itself

Abstract

introductionProduct design is a key tobacco industry strategy to recruit consumers and hinder cessation. An important technology in tobacco product design is the use of additives including those that create characterising flavours, that is, flavours that are perceived by taste and or smell by the user. To curb youth use, many countries are implementing policies to limit the use of flavours and other additives in tobacco products. This paper reviews the global landscape of tobacco additives policies including those focusing only on flavouring additives, updating a previous review.

methodsWe gathered additives policy data from available online sources of tobacco control policies including parties' reports to the WHO Framework Convention on Tobacco Control (where WHO refers to World Health Organization), the website Tobacco Control Laws, government websites, searches with the Google search engine and consultations with the WHO to ensure comprehensiveness of the assessment. The policies were classified according to their objective and characteristics: Labelling regulations, sales bans and tobacco product design regulations. We classified and organised the regulations according to their stated intent.

resultsWe found that 62 countries had tobacco products' additives-related regulations at the regional, national or subnational levels. Most of these regulations focused on flavouring additives especially bans on the selling, importing and manufacturing tobacco products with characterising flavours.

conclusionsThe data demonstrate various global policies addressing additives and/or flavours and a range of definitions of additives and flavours. Establishing common definitions and standards could facilitate cooperation between countries and regions.

Indexed as

Global healthNicotinePublic policyTobacco industry

Identifiers

PMID39401890
PMCPMC12116206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.